Elutia Q4 revenue rises on higher cardiovascular product sales

Reuters03-12

<a href="https://laohu8.com/S/ELUT">Elutia</a> Q4 revenue rises on higher cardiovascular product sales

Overview

Drug-eluting biomatrix maker's Q4 revenue rose 16% yr/yr to $3.3 mln
Net income turned positive, driven by $88 mln BioEnvelope business sale to Boston Scientific
Company repaid all outstanding debt and ended year with $44.4 mln in cash and escrowed proceeds

Outlook

Elutia anticipates FDA clearance for NXT-41 in second half of 2026
Company expects full NXT-41x clearance in first half of 2027

Result Drivers

PRODUCT MIX - Cardiovascular product sales rose, offsetting a decline in SimpliDerm sales
GROSS MARGIN IMPROVEMENT - Gross margin increased due to lower cost of goods sold

Company press release: ID:nGNXF1lsz

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Revenue	Slight Miss*	$3.27 mln	$3.30 mln (1 Analyst)
Q4 EPS		$1.48
Q4 Net Income		$70.79 mln
Q4 Gross Profit		$1.91 mln
Q4 Operating Expenses		$8.48 mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The one available analyst rating on the shares is "buy"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Elutia Inc is $5.00, about 358.7% above its March 10 closing price of $1.09

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618975512?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-12 04:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618975512","market":"nz","top_or_hot":-1,"title":"Elutia Q4 revenue rises on higher cardiovascular product sales","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/ELUT\">Elutia</a> Q4 revenue rises on higher cardiovascular product sales</title></head><body><p><span>Overview</span></p><ul><li><p>Drug-eluting biomatrix maker's Q4 revenue rose 16% yr/yr to $3.3 mln</p></li><li><p>Net income turned positive, driven by $88 mln BioEnvelope business sale to Boston Scientific</p></li><li><p>Company repaid all outstanding debt and ended year with $44.4 mln in cash and escrowed proceeds</p></li></ul><p><span>Outlook</span></p><ul><li><p>Elutia anticipates FDA clearance for NXT-41 in second half of 2026</p></li><li><p>Company expects full NXT-41x clearance in first half of 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>PRODUCT MIX - Cardiovascular product sales rose, offsetting a decline in SimpliDerm sales</p></li><li><p>GROSS MARGIN IMPROVEMENT - Gross margin increased due to lower cost of goods sold</p></li></ul><p>Company press release: <span>ID:nGNXF1lsz</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Slight Miss*</p></td><td><p>$3.27 mln</p></td><td><p>$3.30 mln (1 Analyst)</p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>$1.48</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>$70.79 mln</p></td><td></td></tr><tr><td><p>Q4 Gross Profit</p></td><td></td><td><p>$1.91 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Expenses</p></td><td></td><td><p>$8.48 mln</p></td><td></td></tr></tbody></table><p>*Applies to a deviation of less than 1%; not applicable for per-share numbers.</p><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"buy\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Elutia Inc is $5.00, about 358.7% above its March 10 closing price of $1.09</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Elutia Q4 revenue rises on higher cardiovascular product sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nElutia Q4 revenue rises on higher cardiovascular product sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-12 04:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/ELUT\">Elutia</a> Q4 revenue rises on higher cardiovascular product sales</title></head><body><p><span>Overview</span></p><ul><li><p>Drug-eluting biomatrix maker's Q4 revenue rose 16% yr/yr to $3.3 mln</p></li><li><p>Net income turned positive, driven by $88 mln BioEnvelope business sale to Boston Scientific</p></li><li><p>Company repaid all outstanding debt and ended year with $44.4 mln in cash and escrowed proceeds</p></li></ul><p><span>Outlook</span></p><ul><li><p>Elutia anticipates FDA clearance for NXT-41 in second half of 2026</p></li><li><p>Company expects full NXT-41x clearance in first half of 2027</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>PRODUCT MIX - Cardiovascular product sales rose, offsetting a decline in SimpliDerm sales</p></li><li><p>GROSS MARGIN IMPROVEMENT - Gross margin increased due to lower cost of goods sold</p></li></ul><p>Company press release: <span>ID:nGNXF1lsz</span></p><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Revenue</p></td><td><p>Slight Miss*</p></td><td><p>$3.27 mln</p></td><td><p>$3.30 mln (1 Analyst)</p></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>$1.48</p></td><td></td></tr><tr><td><p>Q4 Net Income</p></td><td></td><td><p>$70.79 mln</p></td><td></td></tr><tr><td><p>Q4 Gross Profit</p></td><td></td><td><p>$1.91 mln</p></td><td></td></tr><tr><td><p>Q4 Operating Expenses</p></td><td></td><td><p>$8.48 mln</p></td><td></td></tr></tbody></table><p>*Applies to a deviation of less than 1%; not applicable for per-share numbers.</p><p><span>Analyst Coverage</span></p><ul><li><p>The one available analyst rating on the shares is \"buy\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Elutia Inc is $5.00, about 358.7% above its March 10 closing price of $1.09</p></li></ul><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1720051017.SGD","symbol_name":"Allianz Global Artificial Intelligence AT Acc H2-SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nL1N3ZZ1C5:1","article_id":"2618975512","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618975512","pubTimestamp":1773260768,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Elutia Q4 revenue rises on higher cardiovascular product salesOverviewDrug-eluting biomatrix maker's Q4 revenue rose 16% yr/yr to $3.3 mlnNet income turned positive, driven by $88 mln BioEnvelope busi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU2506952170.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) INC","LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","LU0238689110.USD":"贝莱德环球动力股票基金","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU0528227936.USD":"富达环球人口趋势基金A-ACC","BK4082":"医疗保健设备","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BSX":"波士顿科学","LU0353189763.USD":"ALLSPRING  US ALL CAP GROWTH FUND \"I\" (USD) ACC","LU1791710582.SGD":"Fidelity Global Demographics A-ACC-SGD (SGD/USD hedged)","LU1548497426.USD":"安联环球人工智能AT Acc","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LU2242649171.HKD":"FIDELITY FUNDS GLOBAL THEMATIC OPPORTUNITIES \"A\" (HKD) ACC","BK4588":"碎股","LU0048584097.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) INC","LU0882574055.USD":"富达全球健康医疗A ACC","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","LU0251132253.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) ACC","LU2506951875.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) ACC","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","LU2506952097.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) ACC","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","ELUT":"Elutia","LU0823417737.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU1153585028.USD":"BGF GLOBAL LONG-HORIZON EQUITY  \"A4\" (USD) INC","LU0823417653.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) ACC","LU0950375773.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC A","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU2491049909.HKD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (HKD) ACC"},"translate_title":"Elutia第四季度收入因心血管产品销量增加而增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSX":0.9,"ELUT":0.9},"content_text":"Elutia Q4 revenue rises on higher cardiovascular product salesOverviewDrug-eluting biomatrix maker's Q4 revenue rose 16% yr/yr to $3.3 mlnNet income turned positive, driven by $88 mln BioEnvelope business sale to Boston ScientificCompany repaid all outstanding debt and ended year with $44.4 mln in cash and escrowed proceedsOutlookElutia anticipates FDA clearance for NXT-41 in second half of 2026Company expects full NXT-41x clearance in first half of 2027Result DriversPRODUCT MIX - Cardiovascular product sales rose, offsetting a decline in SimpliDerm salesGROSS MARGIN IMPROVEMENT - Gross margin increased due to lower cost of goods soldCompany press release: ID:nGNXF1lszKey DetailsMetricBeat/MissActualConsensus EstimateQ4 RevenueSlight Miss*$3.27 mln$3.30 mln (1 Analyst)Q4 EPS$1.48Q4 Net Income$70.79 mlnQ4 Gross Profit$1.91 mlnQ4 Operating Expenses$8.48 mln*Applies to a deviation of less than 1%; not applicable for per-share numbers.Analyst CoverageThe one available analyst rating on the shares is \"buy\"The average consensus recommendation for the pharmaceuticals peer group is \"buy\"Wall Street's median 12-month price target for Elutia Inc is $5.00, about 358.7% above its March 10 closing price of $1.09For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618975512","isCrawlerRequest":true}